Genta said last week that it has signed a deal to acquire Salus Therapeutics, making it the latest in a string of biopharmaceutical companies, including such big players as Abbott and Genentech, to toss their hats into the RNAi ring.
Genta said last week that it has signed a deal to acquire Salus Therapeutics, making it the latest in a string of biopharmaceutical companies, including such big players as Abbott and Genentech, to toss their hats into the RNAi ring.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.